Merck expands its biosafety testing laboratory center in Shanghai

·Further expand its biosafety testing laboratory to meet local demand.

·total investment29 million euros, this expansion is the second phase project of the Biosafety Testing Experimental Center, which will open in 2022.

·Strengthened its presence in the Chinese marketBioReliance ® Biosafety testing service capability.

On November 21, 2023, Shanghai, China - Merck announced the successful completion and official opening of the second phase of its China Biosafety Testing and Experimentation Center project, which was built with a total investment of 29 million euros last year, adding an additional 1500 square meters to the first phase of the project. This testing laboratory center is Merck's biosafety testing facility in the Chinese market, enabling customers to obtain diverse biosafety testing services locally - from preclinical development to cell bank testing and batch release testing required for commercial market launch.

Event guests (from left to right): Mr. Sun Hao, Biosafety Testing Manager of Merck Life Sciences Biopharmaceutical Testing Services, Ms. Tao Juhong, Biosafety Operations Manager of Merck Life Sciences Biopharmaceutical Testing Services in China, and Yantai MabTheri International Biopharmaceutical Co., LtdDr. Li Xinfang, CEO; Mr. Ma Jinrui, Managing Director of Merck Life Sciences China; Mr. Ling Gang, Chief Engineer of Pudong New Area Science and Economic Committee; Dr. Caine Leong, Asia Pacific Business Manager of Merck Life Sciences Biopharmaceutical Testing Services; Dr. Wang Su, Business Manager of Merck Life Sciences Biopharmaceutical Testing Services China; Dr. Alison Armstrong, Global Technology and Scientific Solutions Team Leader and Senior Director of Merck Life Sciences Biopharmaceutical Testing Services

Dirk, Global Head of Life Science Services at Merck Life Sciences Business·Dirk Lange stated that the opening of the Phase II laboratory further deepens our partnership with Chinese clients who are at the forefront of shaping modern medicine. Our biosafety testing experimental center located in Shanghai can now provide localized testing services with over 75 years of international experience for the Chinese market.

The first phase of the Merck China Biosafety Testing and Experimentation Center has opened up a project for virus clearance validation services, which is one of the most critical steps in drug development. The second phase of the project added cell bank verification and batch release testing services to help biopharmaceutical customers ensure the safety, purity, and identification of their cell banks. The testing and experimental center also provides compliant solutions for harvesting and raw materialsBatch release testing services required by GMP to meet the requirements of pre clinical and clinical research biological products, as well as approved biological products.

With the completion of the second phase of the center's construction, Merck can provide a wide range of biosafety testing services for monoclonal antibodies, other recombinant proteins, as well as cell and gene therapies in China. This Shanghai testing and experimental center has become an important member of Merck's global biosafety testing and experimental service network. Other experimental centers providing this service are located in Singapore, Sterling and Glasgow, UK, and Rockville, Maryland, USA, sharing the same global expertise, standards, and operational systems.

(Merck China Biosafety Testing Laboratory Phase II)

MerckBioReliance ® Biosafety testing services provide customers with innovative technology to ensure the safety and quality of the biopharmaceutical industry supply chain. As a leader in the biosafety testing industry, Merck has over 1000 clients worldwide and a broad product portfolio in major therapies such as mAbs, ADCs, CGT, mRNA, and vaccines.